Attached files
| file | filename |
|---|---|
| EX-16.1 - EXHIBIT 16.1 - Medite Cancer Diagnostics, Inc. | v410662_ex16-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
| Date of report (Date of earliest event reported) | May 12, 2015 |
MEDITE CANCER DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 333-143570 | 36-4296006 |
| (Commission File Number) | (IRS Employer Identification No.) |
| 4203 SW 34th St. | |
| Orlando, FL | 32811 |
| (Address of Principal Executive Offices) | (Zip Code) |
(407) 996-9630
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 4.01 Changes in Registrant’s Certifying Accountant
On May 12, 2015, upon the recommendation of the Company’s Audit Committee, the Board of Directors of Medite Cancer Diagnostics, Inc. (the “Company”) dismissed L.J. Soldinger Associates (“LJSA”) as the Company’s independent auditing firm.
The reports of LJSA on the Company’s financial statements for the fiscal years ended December 31, 2014 and 2013, did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. In connection with the audits of the Company’s financial statements for the fiscal years ended December 31, 2013 and 2014, and (1) there were no disagreements with LJSA on any matter of accounting principles or practices, financial statement disclosure or auditing scope and procedure which, if not resolved to the satisfaction of LJSA, would have caused LJSA to make reference to the matter in its report and (2) there were no “reportable events” as that term is defined in Item 304 of Regulation S-K promulgated under the Securities Exchange Act of 1934 (“Item 304”). The Company provided L J Soldinger Associates LLC with a copy of the disclosures made pursuant to this Item 4.01 prior to the filing of this Current Report on Form 8-K.The Company has requested LJSA to furnish it a letter addressed to the Commission stating whether it agrees with the above statements. A copy of that letter, dated May 12, 2015 is filed as Exhibit 16.1 to this Form 8-K.
Item 9.01 Financial Statements and Exhibits
Exhibit No. Description
| 16.1 | Letter dated May 12, 2015 from LJ Soldinger Associates to the Securities and Exchange Commission |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MEDITE CANCER DIAGNOSTICS, INC. | ||
| Date: May 13, 2015 | By: | /s/ Michaela Ott |
| Michaela Ott | ||
| Chief Executive Officer | ||
| 2 |